UroGen Pharma Ltd.URGNNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +20.87% | +4.40% | +7.84% | -100.00% | +9.04% |
| Gross Profit Growth | +23.08% | +4.00% | +5.11% | -100.00% | +6.39% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +33.44% | +30.09% | +42.07% | +29.65% | +11.50% |
| Weighted Average Shares Diluted Growth | +33.44% | +30.09% | +42.07% | +29.65% | +11.50% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +77.49% | +31.46% | +38.71% | +12.83% | -13.59% |
| Inventory Growth | +51.82% | +62.65% | +4.79% | -4.22% | +9.84% |
| Asset Growth | +55.94% | +60.23% | +23.45% | -25.95% | -38.71% |
| Book Value per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Debt Growth | +22.48% | +23.12% | +26.20% | +29.76% | +6.58% |
| R&D Expense Growth | +11.00% | +31.78% | +28.25% | -100.00% | +23.36% |
| SG&A Expenses Growth | +33.03% | -100.00% | +28.09% | -100.00% | +29.86% |